John Gillings
About John Gillings
John Gillings (age 50) joined STRATA Skin Sciences in August 2024 as Vice President of Finance & Administration and was promoted to Chief Accounting Officer in November 2024; prior roles include private equity at Accelmed Partners, Head of Investor Relations at Apollo Endosurgery, and MedTech publishing equity research analyst at JMP Securities. He holds undergraduate and master’s degrees in accounting from the University of Utah and a master’s in finance from London Business School . During his tenure, quarterly revenue fell from $8.797M (Q3 2024) to $6.929M (Q3 2025) while EBITDA improved modestly from -$0.414M to -$0.309M [GetFinancials: S&P Global]*. As of November 14, 2025, Gillings signed the Q3 2025 10‑Q as Principal Financial Officer and executed Sarbanes‑Oxley certifications, evidencing responsibility for disclosure controls and internal control over financial reporting .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Accelmed Partners | Private Equity (medical device focused) | — | Investment and portfolio support in MedTech |
| Apollo Endosurgery | Head of Investor Relations | — | Capital markets and IR leadership |
| JMP Securities | Publishing Equity Research Analyst (MedTech/Medical Devices) | — | Sector coverage, fundamental analysis, and research publication |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Accelmed Partners | PE professional (external to SSKN) | — | Medical device investment focus |
| Apollo Endosurgery | Head of Investor Relations | — | External corporate IR leadership |
| JMP Securities | Equity Research Analyst | — | External sell-side research |
Fixed Compensation
| Component | Amount/Detail | Source |
|---|---|---|
| Base Salary | $225,000 per annum (on joining in Aug 2024) | |
| Target Bonus % | Up to 25% of salary, based on personal and company goals | |
| Actual Bonus Paid (2024) | $0 | |
| Other Compensation (2024) | $5,000 car allowance |
Performance Compensation
| Incentive Type | Metric(s) | Weighting | Target | Actual Payout (2024) | Vesting/Timing |
|---|---|---|---|---|---|
| Annual Cash Bonus | Personal + Company goals (matrix) | Not disclosed | Up to 25% of base salary | $0 | Annual; contingent on goals |
Equity Awards (Grants and Vesting)
| Award Type | Grant Date | Shares Granted | Fair Value (Grant-Date) | Strike/Exercise Price | Expiration | Vesting Schedule |
|---|---|---|---|---|---|---|
| Stock Options (NSO) | 08-13-2024 | 30,000 | $56,460 | $2.71 | 08-13-2034 | Four equal annual installments beginning on the anniversary of the first business day after grant |
| Vest Tranche | Shares | Vesting Detail |
|---|---|---|
| Year 1 | 7,500 | Annual installment; specific dates per award agreement |
| Year 2 | 7,500 | Annual installment |
| Year 3 | 7,500 | Annual installment |
| Year 4 | 7,500 | Annual installment |
Equity Ownership & Alignment
| Item | Detail | Source |
|---|---|---|
| Total Beneficial Ownership (03-31-2025) | 0 shares; less than 1% of outstanding | |
| Options – Exercisable | 0 (FY 2024 year-end) | |
| Options – Unvested | 30,000 (strike $2.71, exp. 08-13-2034) | |
| Shares Pledged as Collateral | Not disclosed in proxy/10‑K reviewed | — |
| Ownership Guidelines | Not disclosed in proxy/10‑K reviewed | — |
| Insider Trading Controls | Quarterly trading window and blackout policy enforced |
Employment Terms
| Provision | Key Terms | Source |
|---|---|---|
| Employment Start / Promotion | Joined Aug 2024 (VP Finance & Admin); promoted CAO Nov 2024 | |
| Change-in-Control Agreement (08-14-2024) | Severance equal to 6 months base salary; pro‑rata annual bonus for year of termination; 6 months continued health/dental/vision eligibility; paid via normal payroll | |
| Clawback Provisions | All awards subject to clawback/recoupment to comply with policy and applicable law |
Performance & Track Record (during tenure)
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|---|
| Revenue (USD) | $8,435,000 | $8,797,000 | $9,576,000* | $6,812,000 | $7,663,000 | $6,929,000 |
| EBITDA (USD) | $764,000* | -$414,000* | $864,000 | -$795,000* | -$1,006,000* | -$309,000* |
Values with an asterisk are retrieved from S&P Global via GetFinancials.
Investment Implications
- Pay-for-performance alignment: Cash bonus opportunity is contingent (up to 25% of salary), with no payout in 2024, while equity is time‑vested options that vest over four years; immediate liquidity from equity is limited given 0 exercisable options at FY‑end 2024 .
- Retention risk: The company disclosed that “outstanding stock options currently have exercise prices significantly higher than our market price,” potentially reducing option-based retention effectiveness broadly across executives .
- Ownership alignment: Gillings reported 0 beneficially owned shares as of March 31, 2025; his alignment is principally through unvested options (30,000) and bonus metrics, with corporate clawback policy in place .
- Execution context: As Principal Financial Officer and CAO, Gillings certified Q3 2025 controls and financials; during his tenure, quarterly revenue declined (Q3 2024→Q3 2025) while EBITDA improved modestly yet remained negative through most of 2025, underscoring a turnaround execution challenge [GetFinancials: S&P Global]*.
*Values retrieved from S&P Global via GetFinancials.